Takeda reports phase III trial findings for Hematide

Takeda and its collaborative partner Affymax have published new clinical trial data from four studies of their investigational drug Hematide.

The treatment, which is designed as a therapy for anaemia in chronic renal failure patients, was able to meet its primary endpoint in the phase III trials by demonstrating non-inferiority to epoetin and darbepoetin.

In addition, the drug was also able to meet the statistical criterion for non-inferiority for the adjudicated cardiovascular composite safety endpoint across the combined trials.

The manufacturers are now hoping to submit the drug for regulatory approval based on the positive findings from the phase III programme.

Dr Azmi Nabulsi, president of Takeda’s global research and development centre, said: “The focus of Takeda and Affymax is patients’ needs, which are paramount in drug development. Together, we are working to bring this treatment option to patients with chronic renal failure.”

Last month, Takeda announced the commencement of a new two-year growth plan, which will see the firm enhance its sales and profitability by focusing on key clinical areas such as cardiovascular illness and oncology.